Further studies should include broader populations and head-to-head comparisons of bupropion/naltrexone with other active weight-loss agents ... of the two component drugs will require careful ...

The study was supported by a company that has combined the two drugs in ... mean weight loss was significantly greater in the high- and low-dose bupropion/naltrexone groups than in the placebo ...

Encouraged by her weight-loss progress, Breen decided to give another member of this class of drugs, known as GLP-1 agonists, ...

the association with bupropion and naltrexone became statistically insignificant when adjusted for weight loss. Researchers hypothesized that certain pharmacological properties of obesity drugs ...

Weight loss medications typically suppress a person ... Contrave belongs to a class of drugs known as bupropion/naltrexone. Bupropion is a type of antidepressant, whereas naltrexone is an ...

The researchers compared the drugs to bupropion-naltrexone, the active ingredient in weight-loss drug Contrave, which was approved in 2014. A Novo Nordisk spokesperson noted that some of the ...

the significance of bupropion and naltrexone's effect disappeared, suggesting the reduction may be mediated by weight loss rather than the medication itself. This is a remarkable finding ...

In a recent study published in the International Journal of Obesity, researchers investigated the effects of combined glucagon-like peptide 1 (GLP-1) analog and bupropion/naltrexone treatment on ...

Encouraged by her weight-loss progress, Breen decided to give another member of this class of drugs, known as GLP-1 agonists, a shot. Eight months after he stopped taking naltrexone, in April 2023 ...